ABLYNX IDENTIFIES NOVEL NANOBODIES® ACHIEVING SECOND MILESTONE IN PROCTER & GAMBLE COLLABORATION

6/18/2007, 8:00 AM (Source: GlobeNewswire)



GHENT, Belgium, 18 June 2007 - Ablynx, the pioneer in the discovery
and development of Nanobodies® has announced that its collaboration
agreement with Procter & Gamble Pharmaceuticals Inc. (P&GP), a
division of The Procter & Gamble Company, has reached a second
milestone. Ablynx has discovered novel Nanobodies® against a second
target for possible new treatments in the musculoskeletal area. The
first milestone under this collaboration was achieved in December
2006 and was also a target for musculoskeletal diseases.

Ablynx's unique and patented Nanobody® technology has been used to
rapidly identify a highly diverse and potent panel of Nanobodies®
against one of the targets exclusive to the collaboration, triggering
a second undisclosed milestone payment.

Hennie R. Hoogenboom, PhD, Chief Scientific Officer at Ablynx, said:
"We are delighted to have met another important milestone as part of
our on-going collaboration with Procter & Gamble. This is yet another
important validation of the speed at which our Nanobody® technology
platform can deliver high quality Nanobodies®. We are very excited to
advance this programme to the next stage together with Procter &
Gamble."

Kevin E. Driscoll, PhD, Director New Technology Development at P&GP
added:
"We are very pleased with the progression of our collaboration with
Ablynx. We are a step closer towards the goal of producing Nanobody®
development candidates in this very important area of musculoskeletal
diseases."

As part of this on-going collaboration Ablynx is responsible for
discovering Nanobodies® that meet an agreed product profile. P&GP is
responsible for the pre-clinical and clinical development of
Nanobodies®, as well as the commercialization of any resulting drug
products.


To open the full PDF version of this press release, please click on
the link below:
Press release in PDF format


Contacts:


Media Relations for Ablynx: At Ablynx:

Mary Clark, Director Dr. Edwin Moses
Capital MS&L Chairman and CEO
t : +44 (0)20 7307 5336 t : +32 (0)9 241 11 51
m: +44 7713 335171 m: +44 (0)7771 954 193 / +32 (0)473
e : mary.clark@capitalmsl.com 39 50 68
e: edwin.moses@ablynx.com
Halina Kukula
Capital MS&L Eva-Lotta Allan
t : +44 (0) 20 7307 5340 Chief Business Officer
e: halina.kukula@capitalmsl.com t : +32 (0)9 261 06 35
m: +32 (0)475 78 36 21 / +44 (0)7990
570 900
e: eva-lotta.allan@ablynx.com


View document
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.